Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer.
Advanced gastric cancer
Glasgow Prognostic Score (GPS)
biomarkers
immune checkpoint inhibitors
nivolumab
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
31
03
2020
revised:
11
04
2020
accepted:
16
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC). AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab. Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival. We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC).
PATIENTS AND METHODS
METHODS
AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab.
RESULTS
RESULTS
Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival.
CONCLUSION
CONCLUSIONS
We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation.
Identifiants
pubmed: 32606164
pii: 34/4/1921
doi: 10.21873/invivo.11989
pmc: PMC7439859
doi:
Substances chimiques
Biomarkers
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1921-1929Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Br J Cancer. 2003 Sep 15;89(6):1028-30
pubmed: 12966420
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Int J Colorectal Dis. 2007 Aug;22(8):881-6
pubmed: 17245566
Clin Cancer Res. 2001 Oct;7(10):3025-30
pubmed: 11595690
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Oncotarget. 2018 Oct 2;9(77):34520-34527
pubmed: 30349646
Tumour Biol. 2012 Jun;33(3):749-56
pubmed: 22198641
Clin Immunol. 2008 Nov;129(2):219-29
pubmed: 18771959
J Immunother Cancer. 2019 Jan 31;7(1):24
pubmed: 30704511
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
Br J Cancer. 2006 Mar 13;94(5):637-41
pubmed: 16479253
Anticancer Res. 2017 Oct;37(10):5885-5891
pubmed: 28982916
Pancreatology. 2006;6(5):450-3
pubmed: 16847382
BMC Cancer. 2019 Oct 21;19(1):974
pubmed: 31638948
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Onco Targets Ther. 2016 Jun 27;9:3883-91
pubmed: 27390529
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Onco Targets Ther. 2018 Feb 23;11:955-965
pubmed: 29503570
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
J Natl Cancer Inst. 2018 Jul 1;110(7):777-786
pubmed: 29267866